The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs. those using a DPP-IV inhibitor. Women may have a lower risk for thyroid cancer ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have shown cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM). Given the risk factor overlap between neurovascular and ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Losing weight can feel like climbing a mountain with no clear path. The one-size-fits-all advice—like “eat less, move ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...

The active GLP-1 RA prescription group had a significantly lower risk for 30-day readmission and 180-day postoperative wound dehiscence and postoperative hematoma after matching. HealthDay News ...